The short life and rapid death of a novel antihypertensive and antianginal agent.
Krum
H
H
McNeil
J J
JJ
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects*; D001919:Bradycardia / Q000139:chemically induced*; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000009:adverse effects*; D016265:Conflict of Interest; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006801:Humans; D020748:Mibefradil; D013610:Tachycardia / Q000139:chemically induced*; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage / Q000009:adverse effects*
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D002121:Calcium Channel Blockers; D013764:Tetrahydronaphthalenes; D020748:Mibefradil